Online inquiry

IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5810MR)

This product GTTS-WQ5810MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Kidney transplant rejection, Psoriasis, Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5810MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3608MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ6920MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ15977MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ13293MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ6473MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ3030MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ8712MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ394MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 20D7S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW